MCK Stock Recent News
MCK LATEST HEADLINES
McKesson (MCK) closed at $586.08 in the latest trading session, marking a -1.1% move from the prior day.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
McKesson MCK has started 2025 on a positive note, with the stock climbing 4% so far in January as investors remain optimistic about the company's performance in 2025. MCK's growth this year will be driven by its strategic focus on oncology and biopharma services, supported by the expansion of The US Oncology Network and the launch of InspiroGene for cell and gene therapies.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson (MCK) concluded the recent trading session at $585.08, signifying a +0.57% move from its prior day's close.
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MCK aims to focus on capital deployment and prioritize investments to strengthen its strategic oncology and biopharma growth platforms.
In the latest trading session, McKesson (MCK) closed at $513.67, marking a +0.86% move from the previous day.